Clinical assistant professor in the Department of Internal Medicine at the University of Texas Rio Grande Valley School of Medicine.
Ethics Hum Res. 2023 Mar;45(2):14-25. doi: 10.1002/eahr.500158.
The prevailing approach to enrolling decisionally impaired adults in clinical research is to rely on permission from a default surrogate, one identified by law rather than by the prospective research participant. Reliance on a surrogate transfers the focus of ethical protection from a researcher-participant relationship to a researcher-surrogate relationship; the selection and role of the surrogate are therefore important. The Common Rule defers to state law governing default surrogate consent to research, but most states have no such law; for those states, the Common Rule defers to institutional policy. I reviewed twenty-five of the study sites with the highest National Institutes of Health funding levels to elaborate the content of institutional review board (IRB) policies and compare those to a suggested paradigm for ethically defensible policies. My findings suggest that IRB policies provide inadequate protection because they recognize surrogates who lack knowledge of the subject's current values and preferences without imposing adequate additional safeguards.
目前,将决策能力受损的成年人纳入临床研究的主流方法是依赖默认代理人的同意,默认代理人是由法律而非潜在研究参与者指定的。依赖代理人将伦理保护的重点从研究人员与参与者的关系转移到研究人员与代理人的关系;因此,代理人的选择和角色很重要。《普遍规则》(Common Rule)遵从州法律来管理默认代理人同意进行研究,但大多数州没有这样的法律;对于这些州,《普遍规则》遵从机构政策。我审查了 NIH 资助水平最高的 25 个研究基地,以详细说明机构审查委员会(IRB)政策的内容,并将其与具有道德可辩护性的政策建议范式进行比较。我的发现表明,IRB 政策提供的保护不足,因为它们承认代理人缺乏对受试者当前价值观和偏好的了解,但没有施加足够的额外保障措施。